恩替卡韦和拉夫米定治疗乙肝的临床效果对比

Comparison of Clinical Effects of Entecavir and Lavumidine in the Treatment of Hepatitis B

目的探讨恩替卡韦和拉夫米定治疗乙肝的临床效果。方法将该院2018年2月—2019年10月期间收治的104例乙肝患者随机分为两组,其中给予对照组拉夫米定治疗,而观察组则运用恩替卡韦治疗,对两组患者的治疗效果进行比较分析。结果治疗前,两组血清HBsAg定量水平比较差异无统计学意义(P>0.05);治疗后12周,两组的HBsAg水平均下降,但是组间比较差异无统计学意义(P>0.05);治疗后24周、48周,观察组的血清HBsAg水平明显低于对照组,差异有统计学意义(P<0.05);观察组的HBV DNA转阴率和HBsAg定量<2500 IU/mL百分比分别为75.00%、25.00%,而对照组则为53.85%、5.77%,差异有统计学意义(χ^(2)=5.076、7.386,P<0.05);同时,观察组的ALT、HBeAg以及HBV DNA水平分别为(70.2±10.3)U/L、(77.4±20.5)COI、(8.5±2.1)×10^(5) IU/mL,而对照组则为(83.4±9.5)U/L、(89.2±21.3)COI、(9.8±1.7)×10^(5) IU/mL,组间比较差异有统计学意义(t=6.793、2.878、3.470,P<0.05)。结论在乙肝患者的临床治疗中,与拉夫米定相比,恩替卡韦不仅可以降低血清HBsAg水平,还能提高HBV DNA转阴率,获得较好的治疗效果,有助于改善患者预后,具有一定的推广运用价值。

Objective To explore the clinical effects of entecavir and lafmididine in the treatment of hepatitis B.Methods The 104 hepatitis B patients admitted to the hospital from February 2018 to October 2019 were randomly divided into two groups.Among them,the control group was treated with lavmidine and the observation group was treated with entecavir.The treatment effects of the two groups of patients were compared and analyzed.Results Before treatment,there was no statistically significant difference in the quantitative level of serum HBsAg between the two groups(P>0.05);12 weeks after treatment,the HBsAg level of the two groups decreased,but the difference between the groups was not statistically significant(P>0.05);After 24 weeks and 48 weeks,the serum HBsAg level of the observation group was significantly lower than that of the control group,the difference was statistically significant(P<0.05);the HBV DNA conversion rate and the percentage of HBsAg quantitative<2500 IU/mL in the observation group were 75.00%,respectively 25.00%,while the control group were 53.85%,5.77%,the difference was statistically significant(χ^(2)=5.076,7.386,P<0.05);at the same time,the observation group's ALT,HBeAg and HBV DNA levels were(70.2±10.3)U/L,(77.4±20.5)COI,(8.5±2.1)×10^(5) IU/mL,while the control group were(83.4±9.5)U/L,(89.2±21.3)COI,(9.8±1.7)×10^(5) IU/mL,the difference between the groups was statistically significant(t=6.793,2.878,3.470,P<0.05).Conclusion In the clinical treatment of hepatitis B patients,entecavir can not only reduce the serum HBsAg level,but also increase the rate of HBV DNA conversion to obtain better therapeutic effects compared with lavmidine.It is helpful to improve the prognosis of patients,and has certain promotion and application value.